JP2010517513A5 - - Google Patents

Download PDF

Info

Publication number
JP2010517513A5
JP2010517513A5 JP2009547285A JP2009547285A JP2010517513A5 JP 2010517513 A5 JP2010517513 A5 JP 2010517513A5 JP 2009547285 A JP2009547285 A JP 2009547285A JP 2009547285 A JP2009547285 A JP 2009547285A JP 2010517513 A5 JP2010517513 A5 JP 2010517513A5
Authority
JP
Japan
Prior art keywords
antibody
seq
human
isolated antibody
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009547285A
Other languages
English (en)
Japanese (ja)
Other versions
JP5618544B2 (ja
JP2010517513A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/000884 external-priority patent/WO2008091641A2/en
Publication of JP2010517513A publication Critical patent/JP2010517513A/ja
Publication of JP2010517513A5 publication Critical patent/JP2010517513A5/ja
Application granted granted Critical
Publication of JP5618544B2 publication Critical patent/JP5618544B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009547285A 2007-01-24 2008-01-24 癌の診断および処置のための組成物および方法 Expired - Fee Related JP5618544B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88641407P 2007-01-24 2007-01-24
US60/886,414 2007-01-24
PCT/US2008/000884 WO2008091641A2 (en) 2007-01-24 2008-01-24 Compositions and methods for diagnosing and treating cancer

Publications (3)

Publication Number Publication Date
JP2010517513A JP2010517513A (ja) 2010-05-27
JP2010517513A5 true JP2010517513A5 (enExample) 2011-03-10
JP5618544B2 JP5618544B2 (ja) 2014-11-05

Family

ID=39645070

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009547285A Expired - Fee Related JP5618544B2 (ja) 2007-01-24 2008-01-24 癌の診断および処置のための組成物および方法

Country Status (6)

Country Link
US (4) US8088617B2 (enExample)
EP (1) EP2125887A4 (enExample)
JP (1) JP5618544B2 (enExample)
AU (1) AU2008209482B2 (enExample)
CA (1) CA2676008A1 (enExample)
WO (1) WO2008091641A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906116B2 (en) * 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
JP2009539403A (ja) 2006-06-13 2009-11-19 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌を診断および処置するための組成物および方法
CA2676008A1 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
BRPI0914007A2 (pt) 2008-07-08 2015-11-17 Oncomed Pharm Inc anatagonistas e agentes de ligação de notch e métodos para uso dos mesmos
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
US9475855B2 (en) * 2008-08-22 2016-10-25 The Trustees Of Columbia University In The City Of New York Human Notch3 based fusion proteins as decoy inhibitors of Notch3 signaling
JP5710487B2 (ja) * 2008-10-01 2015-04-30 ジェネンテック, インコーポレイテッド 抗notch2抗体および使用方法
WO2010141249A2 (en) * 2009-06-02 2010-12-09 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-notch3 antibodies
AU2010300747A1 (en) * 2009-09-30 2012-04-26 Genentech, Inc. Treating Notch1-antagonist-resistant cancer (s) using Notch3 antagonists
ES2561102T3 (es) 2010-01-13 2016-02-24 Oncomed Pharmaceuticals, Inc. Agentes de unión a Notch1 y procedimientos de uso de los mismos
WO2012003472A1 (en) * 2010-07-02 2012-01-05 Aveo Pharmaceuticals, Inc. Anti-notch1 antibodies
AR088048A1 (es) * 2011-10-04 2014-05-07 Univ Columbia Señuelos notch1 humanos
US9352039B2 (en) 2012-02-09 2016-05-31 The Regents Of The University Of Michigan Method of reducing the number of EMT and MET type breast cancer stem cells
JP6352264B2 (ja) * 2012-08-13 2018-07-04 ジェネンテック, インコーポレイテッド 抗jagged抗体および使用方法
WO2014100435A1 (en) * 2012-12-19 2014-06-26 Aveo Pharmaceuticals, Inc. Anti-notch3 antibodies
US9944700B2 (en) 2013-03-13 2018-04-17 Novartis Ag Notch2 binding molecules for treating respiratory diseases
JP2016514130A (ja) * 2013-03-14 2016-05-19 ノバルティス アーゲー Notch3に対する抗体
WO2014172653A2 (en) * 2013-04-19 2014-10-23 Aveo Pharmaceuticals, Inc. Anti-notch1 antibodies
EP3166627A1 (en) 2014-07-11 2017-05-17 Genentech, Inc. Notch pathway inhibition
US11142573B2 (en) 2016-04-29 2021-10-12 Aveo Pharmaceuticals, Inc. Anti-Notch3 antibody
CN111349166B (zh) * 2018-12-20 2022-11-08 东莞市朋志生物科技有限公司 一种抗人ca72-4糖蛋白的重组抗体

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1446973A (en) * 1973-09-24 1976-08-18 Asahi Chemical Ind Method of removing nitrogen monoxide from a nitrogen mono xide-containing gas
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3370324B2 (ja) 1991-04-25 2003-01-27 中外製薬株式会社 ヒトインターロイキン−6受容体に対する再構成ヒト抗体
IL101728A (en) 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
IE20030749A1 (en) * 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US20050112121A1 (en) * 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
WO1996036361A1 (en) 1995-05-18 1996-11-21 The Regents Of The University Of Michigan Dna binding antibodies
WO1997037004A1 (en) 1996-03-30 1997-10-09 Boehringer Mannheim Gmbh Method for the production of activated marked tumor-specific t cells and use thereof in treatment of tumors
WO1997045143A1 (en) * 1996-05-31 1997-12-04 The National American Red Cross Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
FR2751986B1 (fr) * 1996-08-01 1998-12-31 Inst Nat Sante Rech Med Gene implique dans le cadasil, methode de diagnostic et application therapeutique
WO1998020142A1 (en) 1996-11-07 1998-05-14 Lorantis Limited Notch
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
WO1998057621A1 (en) 1997-06-18 1998-12-23 The Trustees Of Columbia University In The City Ofnew York Angiogenic modulation by notch signal transduction
US6379925B1 (en) 1997-06-18 2002-04-30 The Trustees Of Columbia University In The City Of New York Angiogenic modulation by notch signal transduction
US6692919B1 (en) 1997-07-23 2004-02-17 Yale University Activated forms of notch and methods based thereon
US7361336B1 (en) * 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US6004528A (en) * 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
WO2000020576A2 (en) 1998-10-02 2000-04-13 The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services, The National Institutes Of Health Methods and compositions for inducing differentiation and apotosis in cells that overexpess the notch protein
US20030003572A1 (en) 1999-03-05 2003-01-02 David J. Anderson Isolation and enrichment of neural stem cells from uncultured tissue based on cell-surface marker expression
US20020010320A1 (en) 1999-04-05 2002-01-24 James W. Fett Chemeric and humanized antibodies to angiogenin
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20030031670A1 (en) * 1999-11-08 2003-02-13 Jack R. Wands Diagnosis and treatment of malignant neoplasms
DE10031380A1 (de) 2000-06-28 2002-01-10 Merck Patent Gmbh Verfahren zur Übertragung von Alkyliden-Gruppen auf organischen Verbindungen
US20080194022A1 (en) 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
AU2001288628A1 (en) 2000-08-31 2002-03-13 Loyola University Chicago Method and reagents for treatment of skin disorders by modulating the notch pathway
US6689744B2 (en) * 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
JP2004517636A (ja) 2000-10-02 2004-06-17 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー B型肝炎ウイルスの表面抗原sに対するヒト化抗体及びその製造方法
JP4406206B2 (ja) 2001-04-24 2010-01-27 バイエル コーポレーション ヒトtimp−1抗体
US7356224B2 (en) * 2001-07-03 2008-04-08 Brown University Research Foundation Method and apparatus for detecting multiple optical wave lengths
AU2002339157A1 (en) 2001-11-14 2003-05-26 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
EP1461023A4 (en) 2001-12-07 2005-08-31 Univ Michigan Prospective Identification and Characterization of Breast Cancer Strain Cells
GB0201674D0 (en) 2002-01-25 2002-03-13 Lorantis Ltd Medical treatment
WO2004001004A2 (en) 2002-06-21 2003-12-31 Johns Hopkins University School Of Medicine Membrane associated tumor endothelium markers
CA2503390A1 (en) * 2002-11-01 2004-05-21 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004052389A2 (en) 2002-12-06 2004-06-24 Singapore General Hospital Pte Ltd. Nogo, caspr, f3 nb-3 useful in the treatment of injury and disease to the central nervous system
EP2060918A3 (en) 2003-04-01 2009-08-26 The Johns Hopkins University Breast endothelial cell expression patterns
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
GB0321805D0 (en) 2003-09-18 2003-10-15 Univ Wales Medicine Human tumour growth patterns
CA2546017A1 (en) 2003-11-26 2005-06-16 Health Research, Inc. Use of notch pathway interfering agents for treatment of plasma cell disorders
JP2007526455A (ja) 2004-02-03 2007-09-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法
CA2560760A1 (en) * 2004-03-24 2005-09-29 Technion Research And Development Foundation Ltd. Electrode
WO2005111072A2 (en) * 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
US20070077245A1 (en) 2004-08-04 2007-04-05 The Brigham And Women's Hospital, Inc. NOTCH mutations leading to increased receptor signaling
GB0421838D0 (en) * 2004-09-30 2004-11-03 Congenia S R L Cancer markers
WO2006053063A2 (en) 2004-11-05 2006-05-18 The Regents Of The University Of California Notch-1 assay to detect neurodegenerative diseases
NZ555216A (en) * 2004-11-10 2010-05-28 Hubrecht Lab Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation
WO2006051405A2 (en) * 2004-11-12 2006-05-18 Cambridge University Technical Services Ltd. Methods and means related to cancer stem cells
EP2083088A3 (en) 2005-04-07 2009-10-14 Novartis Vaccines and Diagnostics, Inc. Cancer-related genes
WO2007061988A2 (en) 2005-11-22 2007-05-31 University Of Vermont And State Agricultural College Methods for determining notch signaling and uses thereof
WO2007075914A2 (en) 2005-12-22 2007-07-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies against orthopoxviruses
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
US20080241150A1 (en) 2006-05-15 2008-10-02 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1
JP2009539403A (ja) 2006-06-13 2009-11-19 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌を診断および処置するための組成物および方法
EP2066694B1 (en) * 2006-09-29 2015-11-04 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2008136848A2 (en) 2006-10-19 2008-11-13 Genentech Inc. Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
WO2008048680A2 (en) * 2006-10-19 2008-04-24 Maine Medical Center Research Institute Notch 2 signaling as a breast cancer suppressor pathway
TW200824707A (en) * 2006-10-19 2008-06-16 Genentech Inc Anti-Notch3 agonist antibodies and their use in the treatment of Notch3-related diseases
US20100068688A1 (en) 2006-11-06 2010-03-18 Howard Shapiro Management of teaching processes for individualized instruction in a multistudent environment
CL2007003661A1 (es) * 2006-12-18 2008-07-18 Genentech Inc Regiones de cadena pesada variable y liviana variable; acidos nucleicos que las codifican; metodo de produccion; anticuerpos anti-notch3 que las comprenden; y uso de los anticuerpos para tratar enfermedades relacionadas con el receptor notch3.
CA2676008A1 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US20090208491A1 (en) 2007-02-14 2009-08-20 Austin Gurney Compositions and Methods for Diagnosing and Treating Cancer
EP2134356A2 (en) 2007-03-05 2009-12-23 Board of Regents, The University of Texas System Negative genetic regulation of cancer cell renewal in synergy with notch- or numb-specific immunotherapy
WO2008109075A2 (en) 2007-03-05 2008-09-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
PL2176296T3 (pl) 2007-07-16 2012-07-31 Genentech Inc Przeciwciała anty-CD79B i immunokoniugaty i sposoby stosowania
NZ583649A (en) 2007-08-23 2012-06-29 Univ Columbia Compositions of humanized notch fusion proteins and methods of treatment
US20110166028A1 (en) 2007-08-28 2011-07-07 Donald Bergstrom Methods for predicting treatment response based on the expression profiles of biomarker genes in notch mediated cancers
WO2009036167A1 (en) 2007-09-14 2009-03-19 Vanderbilt University Targeting of notch3 receptor function for cancer therapy
WO2009035522A1 (en) 2007-09-14 2009-03-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
US20120082659A1 (en) 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
US8119366B2 (en) 2007-10-05 2012-02-21 Trojan Technologies, Ltd. Antennapedia-dominant negative mastermind-like construct
CN102056945A (zh) 2008-04-07 2011-05-11 埃博灵克斯股份有限公司 针对Notch途径的单可变结构域
BRPI0914007A2 (pt) 2008-07-08 2015-11-17 Oncomed Pharm Inc anatagonistas e agentes de ligação de notch e métodos para uso dos mesmos
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
JP5710487B2 (ja) 2008-10-01 2015-04-30 ジェネンテック, インコーポレイテッド 抗notch2抗体および使用方法
WO2010105207A1 (en) 2009-03-13 2010-09-16 The Regents Of The University Of California Prebiotic oligosaccharides
AU2010300747A1 (en) 2009-09-30 2012-04-26 Genentech, Inc. Treating Notch1-antagonist-resistant cancer (s) using Notch3 antagonists
DE102009047243A1 (de) 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
ES2561102T3 (es) 2010-01-13 2016-02-24 Oncomed Pharmaceuticals, Inc. Agentes de unión a Notch1 y procedimientos de uso de los mismos
KR20120117931A (ko) 2010-02-12 2012-10-24 온코메드 파마슈티칼스, 인크. 폴리펩타이드를 발현하는 세포를 확인 및 분리하는 방법
JP5450221B2 (ja) 2010-04-14 2014-03-26 株式会社神戸製鋼所 高電流密度ガスシールドアーク溶接方法
HRP20190047T1 (hr) 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Protutijela koja se vežu na csf1r
WO2012003472A1 (en) 2010-07-02 2012-01-05 Aveo Pharmaceuticals, Inc. Anti-notch1 antibodies
WO2012080926A2 (en) 2010-12-15 2012-06-21 Wyeth Llc Anti-notch1 antibodies
TR201909840T4 (tr) 2011-03-11 2019-07-22 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antikorları ve kullanımları.
JP2015505668A (ja) 2011-11-16 2015-02-26 オンコメッド ファーマシューティカルズ インコーポレイテッド ヒトnotch受容体変異およびその使用
US20130323266A1 (en) 2012-05-16 2013-12-05 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with notch2/3 antibodies
CN105025904A (zh) 2012-09-04 2015-11-04 埃莱森制药有限责任公司 用顺铂脂质复合物预防癌症的肺部复发
CA2885659A1 (en) 2012-09-21 2014-03-27 Oncomed Pharmaceuticals, Inc. Methods of treating hematological malignancies with notch1 antibodies
WO2014072897A1 (en) 2012-11-07 2014-05-15 Pfizer Inc. Anti-notch3 antibodies and antibody-drug conjugates
US20160030561A1 (en) 2013-03-15 2016-02-04 Oncomed Pharmaceuticals, Inc. Methods of Treating Pancreatic Cancer
CN106659778A (zh) 2014-03-07 2017-05-10 昂考梅德药品有限公司 用Notch1抗体治疗癌症的方法
WO2015153997A2 (en) 2014-04-04 2015-10-08 Oncomed Pharmaceuticals, Inc. Notch3 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2010517513A5 (enExample)
JP2020501531A5 (enExample)
JP2018505177A5 (enExample)
RU2019116624A (ru) Новые анти_cd137 антитела и их применение
JP2019513018A5 (enExample)
JP2019533719A5 (enExample)
JP2010532169A5 (enExample)
JP2017519759A5 (enExample)
JP2015500207A5 (enExample)
JP2015509947A5 (enExample)
JP2014531201A5 (enExample)
JP2010534478A5 (enExample)
ME02371B (me) Sastojci i postupci za dijagnstikovanje i tretman raka
RU2014113304A (ru) Анти-cd40-антитела, применение и методы
JP2009541492A5 (enExample)
JP2017529838A5 (enExample)
JP2018506961A5 (enExample)
JPWO2021139777A5 (enExample)
JP2016538832A5 (enExample)
JP2021512159A5 (enExample)
JP2024016024A5 (enExample)
JP2013521252A5 (enExample)
JPWO2021222544A5 (enExample)
AU2019306113B2 (en) Anti-human PD-L1 antibodies and their uses
JPWO2020227457A5 (enExample)